Comparative effectiveness of vildagliptin in combination with other oral anti-diabetes agents in usual-care conditions: the EDGE-Latin America study

Abstract Objective: To assess the proportion of patients on vildagliptin add-on dual therapy who respond to treatment over a 12 month follow-up, relative to comparator oral anti-diabetes dual therapy, in a usual care setting. Research design and methods: Participants were patients with type 2 diabet...

Full description

Saved in:
Bibliographic Details
Published in:Current medical research and opinion 2014-09, Vol.30 (9), p.1769-1776
Main Authors: Mendivil, Carlos O., Márquez-Rodríguez, Eduardo, Ángel, Iván D., Paz, Gustavo, Rodríguez, Cruz, Almada, Jorge, Szyskowsky, Ofelia
Format: Article
Language:English
Subjects:
Adamantane - analogs & derivatives
Adamantane - therapeutic use
Administration, Oral
Adult
Aged
Anti-diabetics
Biomarkers - blood
Comparative Effectiveness Research
Diabetes
Diabetes Mellitus, Type 2 - blood
Diabetes Mellitus, Type 2 - drug therapy
Dipeptidyl peptidase-IV inhibitors
Drug Therapy, Combination
Female
Follow-Up Studies
Glycated Hemoglobin A - metabolism
Humans
Hypoglycemic Agents - therapeutic use
Latin America
Male
Middle Aged
Nitriles - therapeutic use
Prospective Studies
Pyrrolidines - therapeutic use
Treatment Outcome
Vildagliptin
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Objective: To assess the proportion of patients on vildagliptin add-on dual therapy who respond to treatment over a 12 month follow-up, relative to comparator oral anti-diabetes dual therapy, in a usual care setting. Research design and methods: Participants were patients with type 2 diabetes (T2DM) aged 18 years and older from 311 centers in Argentina, Colombia, Ecuador, Mexico and Venezuela. Patients were taking monotherapy with an oral anti-diabetes drug (OAD), and were prescribed a new add-on OAD based on the judgment of their personal physician. According to this choice, patients were assigned to one of the two cohorts: vildagliptin or comparator OADs. Main outcome measures: The primary endpoint was the proportion of patients achieving an A1c drop >0.3% without edema, hypoglycemia, weight gain or discontinuation due to gastrointestinal (GI) events. The secondary endpoint was the proportion of patients with baseline A1c 7% who reached the goal of an A1c
ISSN:0300-7995
1473-4877
DOI:10.1185/03007995.2014.928274